The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sevostyanova E.V.

Federal Research Center for Fundamental and Translational Medicine

Nikolaev Yu.A.

Federal Research Centre for Fundamental and Translational Medicine

Mitrofanov I.M.

Federal Research Center for Fundamental and Translational Medicine

Polyakov V.Ya.

Federal Research Center for Fundamental and Translational Medicine

Uric acid as one of the markers of polymorbidity in patients with coronary heart disease

Authors:

Sevostyanova E.V., Nikolaev Yu.A., Mitrofanov I.M., Polyakov V.Ya.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2022;25(1): 71‑77

DOI: 10.17116/profmed20222501171

Read: 1136 times

Download PDF (RU)
Contact the author
Table of contents

URIC ACID AS ONE OF THE MARKERS OF POLYMORBIDITY IN PATIENTS WITH CORONARY HEART DISEASE
URIC ACID AS ONE OF THE MARKERS OF POLYMORBIDITY IN PATIENTS WITH CORONARY HEART DISEASE

To cite this article:

Sevostyanova EV, Nikolaev YuA, Mitrofanov IM, Polyakov VYa. Uric acid as one of the markers of polymorbidity in patients with coronary heart disease. Russian Journal of Preventive Medicine. 2022;25(1):71‑77. (In Russ.)
https://doi.org/10.17116/profmed20222501171

 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cyto­kine profile in middle-aged men with acute and chro­nic coro­nary syndrome and its rela­tion with coro­nary bed lesion seve­rity. Russian Journal of Preventive Medi­cine. 2024;(10):101-107
Features of como­rbidity pathology in young people. Russian Journal of Preventive Medi­cine. 2024;(11):63-69
Inde­pendent adve­rse outcomes predictors in patients with stable coro­nary heart disease after sche­duled percutaneous coro­nary inte­rventions. Russian Journal of Preventive Medi­cine. 2024;(11):94-101
Improving an auto­matic stress test analysis protocol as a problem solu­tion for sympatho-dependent arrhythmias identification. Russian Journal of Preventive Medi­cine. 2024;(11):115-121
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Prediction of myocardial contractility after coro­nary bypass surgery acco­rding to preoperative contrast-enhanced cardiac magnetic reso­nance imaging and echo­cardiography data. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):506-511
Prognostic role of frailty in early and long-term prognosis after coro­nary artery bypass grafting. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):512-518
Reha­bilitation pote­ntial of patients with ischemic heart disease who unde­rwent auto­venous coro­nary artery bypass surgery in the evaluation of reha­bilitation treatment effe­ctiveness. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):29-39
Cost-effectiveness of using rubi­dium-82 chlo­ride perfusion PET for planning myocardial reva­scularization procedures. Piro­gov Russian Journal of Surgery. 2024;(12-2):58-65
Mode­rate ischemic mitral insu­fficiency with severe left ventricular dysfunction: surgical treatment depe­nding on predictors of adve­rse long-term outcomes. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):651-659
Abstract:

The problem of prevention and treatment of coronary artery disease (CAD) is a variety of diseases associated with this pathology. Until now, the mechanisms of the formation of polymorbidity (PM) remain unclear and biochemical markers of PM have not been identified, which is necessary for the development of effective measures for the prevention and correction of this condition.

OBJECTIVE

To study the relationship between the level of concentration in blood serum of uric acid (UA) with PM and some hemodynamic and metabolic risk factors for chronic non-infectious diseases (CNID) in patients with coronary artery disease.

MATERIAL AND METHODS

A retrospective study of the clinical and biochemical data of patients with chronic coronary artery disease who were examined and treated at the clinic of the Novosibirsk Federal Research Center for Fundamental and Translational Medicine was carried out. The analysis included data from 3073 patients who were divided into 2 groups depending on the concentration of UA in the blood serum: normal and elevated levels. A comparative analysis of the severity of PM, as well as clinical, hemodynamic and biochemical parameters characterizing the risk factors for CNID, in the selected groups was carried out.

RESULTS

It was found that patients with coronary artery disease with increased values of the concentration of UA in the blood serum had higher indicators of trans-system and transnosological PM, systolic blood pressure, body mass index, lipid metabolism disorders (in the form of an increase in the content of total cholesterol, triglycerides, an increase in the atherogenic index). Among patients with coronary artery disease with hyperuricemia, hypercholesterolemia, hypertriglyceridemia, high-density hypolipoproteinemia and hyperglycemia were more often recorded.

CONCLUSION

The concentration of UA in the blood serum of patients with coronary artery disease can serve as one of the biochemical markers of PM. The results obtained can serve as a basis for the development of a method for assessing a patient’s condition in this disease.

Keywords:

uric acid
hyperuricemia
coronary heart disease
polymorbidity
blood pressure
obesity
lipids

Authors:

Sevostyanova E.V.

Federal Research Center for Fundamental and Translational Medicine

Nikolaev Yu.A.

Federal Research Centre for Fundamental and Translational Medicine

Mitrofanov I.M.

Federal Research Center for Fundamental and Translational Medicine

Polyakov V.Ya.

Federal Research Center for Fundamental and Translational Medicine

Received:

03.09.2021

Accepted:

15.10.2021

Close metadata

References:

  1. Oganov RG, Drapkina OM. Polymorbidity: patterns of formation and principles of the combination of several diseases in one patient. Cardiovascular therapy and prevention. 2016;15(4):4-9. (In Russ.). https://doi.org/10.15829/1728-8800-2016-4-4-9
  2. Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210-217.  https://doi.org/10.1136/annrheumdis-2014-206410
  3. Kuo CF, Luo SF. Gout: Risk of premature death in gout unchanged for years. Nat Rev Rheumatol. 2017;13(4):200-201.  https://doi.org/10.1038/nrrheum.2017.27
  4. Oganov RG, Denisov IN, Simanenkov VI, Bakulin IG, Bakulina NV, Boldueva SA, Barbarash ON, Garganeeva NP, Doshchicin VL, Drapkina OM, Dudinskaya EN, Kotovskaya YuV, Lila AM, Mamedov MN, Mardanov BU, Miller ON, Petrova MM, Pozdnyakov YuM, Runihina NK, Sajganov SA, Tarasov AV, Tkacheva ON, Urinskij AM, Shal’nova SA. Comorbidities in practice. Clinical guidelines. Cardiovascular therapy and prevention. 2017; 16(6):5-56. (In Russ.). https://doi.org/10.15829/1728-8800-2017-6-5-56
  5. Fomin VV, Morozova TE, Curko VV. Hyperuricemia, gout and high cardiovascular risk — how to manage them in clinical practice. Therapeutic archive. 2019;12:75-83. (In Russ.). https://doi.org/10.26442/00403660.2019.12.000173
  6. Topolyanskaya SV. Hyperuricemia and cardiovascular diseases. Therapy. 2020;7:71-82. (In Russ.). https://doi.org/10.18565/therapy.2020.7.71-82
  7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis K, Aboyans V, Desormais I. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(12):2284-2309. https://doi.org/10.1097/HJH.0000000000001961
  8. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, Barbarash OL, Boitsov SA, Vavilova TV, Villevalde SV, Galyavich AS, Glezer MG, Grineva EN, Grinstein YuI, Drapkina OM, Zhernakova YuV, Zvartau NE, Kislyak OA, Koziolova NA, Kosmacheva ED, Kotovskaya YuV, Libis RA, Lopatin YuM, Nebiridze DV, Nedoshivin AO, Ostroumova OD, Oschepkova EV, Ratova LG, Skibitsky VV, Tkacheva ON, Chazova IE, Chesnikova AI, Chumakova GA, Shalnova SA, Shestakova MV, Yakushin SS, Yanishevsky SN. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). https://doi.org/1560-4071-2020-3-3786
  9. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta — analysis of observational studies. Arthritis Res Ther. 2015;17(1):90.  https://doi.org/10.1186/s13075-015-0610-9
  10. Richette P, Clerson P, Perissin L, Flipo R-M, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis. 2015;74(1):142-147.  https://doi.org/10.1136/annrheumdis-2013-203779
  11. Rho YH, Lu N, Peloquin CE, Man A, Zhu Y, Zhang Y, Choi HK. Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016; 75(1):91-95.  https://doi.org/10.1136/annrheumdis-2014-205827
  12. Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Benefits of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Therapeutic archive. 2020;92(5):110-118. (In Russ.). https://doi.org/10.26442/00403660.2020.05.000633
  13. Sevost’janova EV, Nikolaev YuA, Mitrofanov IM, Poljakov VYa. Regional features of influence of risk factors for chronic non-communicable diseases on formation of polymorbid pathology. Human Ecology. 2019;3:38-45. (In Russ.). https://doi.org/10.33396/1728-0869-2019-3-38-45
  14. Knuuti J. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Russian Journal of Cardiology. 2020;25(2):3757. (In Russ.). https://doi.org/10.15829/1560-4071-2020-2-3757
  15. Kuwabara M, Borghi C, Cicero AF, Hisatome I, Niwa K, Ohno M, Johnson RJ, Lanaspa MA. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol. 2018;261:183-188.  https://doi.org/10.5603/CJ.2018.0116
  16. Eliseev MS, Novikova AM. Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy. Therapeutic archive. 2019;91(5):120-128. (In Russ.). https://doi.org/10.26442/00403660.2019.05.000232
  17. Eliseev MS. Cardiovascular diseases in gout and urate-lowering therapy. Therapy. 2021;1:108-115. (In Russ.). https://doi.org/10.18565/therapy.2021.1.108-115
  18. Cicero AFG, Fogacci F, Giovannini M, Grandi E, Rosticci M, D’Addato S, Borghi C. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Sci Rep. 2018;8(1):11529. https://doi.org/10.1038/s41598-018-29955-w
  19. Efremov LI, Komisarenko IA. Metabolic continuum and polymorbidity in geriatrics. Experimental and Clinical Gastroenterology. 2014;6(106):4-7. (In Russ.).
  20. Biscaglia S, Ceconi C, Malagù M, Pavasini R, Ferrari R. Uric acid and coronary artery disease: An elusive link deserving further attention. International Journal of Cardiology. 2016;213:28-32.  https://doi.org/10.1016/j.ijcard.2015.08.086
  21. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10:654-661.  https://doi.org/10.1038/nrrheum.2014.124
  22. Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018; 100:1-19.  https://doi.org/10.1016/j.vph.2017.05.005
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.